Biotechnology

Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment

November 25, 2024 5:20 PM

Empyrean Therapeutics, Inc., a pioneering biopharmaceutical company, today announced the successful acquisition of a first-in-class novel TLR-2 antagonist molecule from Eos Therapies, Inc. This strategic move aims to accelerate the development of a new, safe, and effective cancer drug targeting brain, pancreatic, breast, and other hard-to-treat cancers. Designated EMS-312, it is currently in the pre-investigational new drug (pre-IND) phase and...

Read more

MRES: Dr. Esmarilda Dankaert Appointed Chief Innovation Officer (CINO) at M2Bio Sciences

November 25, 2024 9:00 AM

The Institute of Biomedical Research Corp. (OTC PINK:MRES), operating as M2Bio Sciences, is a pioneering biotechnology company dedicated to advancing health and wellness through innovative science-driven solutions. Specialising in researching, developing, and commercialising cutting-edge products in nutrition, health, and sustainability. The company is also committed to groundbreaking research in mental health, gut and oral health, longevity,...

Read more

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

November 25, 2024 8:35 AM

TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided a business update and outlined upcoming targeted milestones. "We have made significant progress toward accomplishing our 2024 corporate objectives, including reaching a Special Protocol Assessment agreement with the FDA by working...

Read more

Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies

November 25, 2024 8:00 AM

Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, today announced it has successfully raised an aggregate $11 million as an initial Series A round to take MOTYS™ into Phase 3 clinical studies. SPRIM Global Investments (SGI), a prominent health sciences investment firm, is leading the round. Doron's most advanced product, MOTYS™, is an intra-articular biologic drug developed for the...

Read more

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

November 22, 2024 9:15 AM

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Watch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / November 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative...

Read more

Therabene Inc. Press Release

November 21, 2024 2:10 PM

Therabene Inc., an emerging biotech company at the forefront of developing advanced cancer therapies, is pleased to announce positive preclinical results for two new novel molecules targeting aggressive cancers. Conducted in collaboration with local biotech service provider Biocytogen, the study results highlight the efficacy of Therabene's innovative approach to cancer treatment, with both new molecules demonstrating compelling tumor reduction...

Read more

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

November 21, 2024 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster...

Read more

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

November 20, 2024 6:25 PM

Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI) , a leading biotech company at the forefront of next-generation pharmaceuticals addressing the root causes of neurological disorders, is encouraged by the U.S. government's progressive stance on the psychedelic industry. The administration's decision to nominate a new Health Secretary with a history of supporting innovative mental health solutions marks a...

Read more

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

November 20, 2024 8:30 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium in New York City. The definitive one-year data supports the application submitted earlier this week by enVVeno Medical...

Read more

A New Stem Cell Therapy for Parkinson's Disease Has Been Confirmed Safe and Effective for the First Time

November 19, 2024 3:25 PM

Nature Cell Co., Ltd., a leading biotech company based in Korea, announced on November 19th that it has confirmed the success of a new treatment involving the intravenous and spinal cavity administration of autologous adipose stem cells. This treatment was developed in collaboration with Japan Angel Stem Cell (JASC) and R Bio, which utilized stem cell culture media produced and supplied by Nature Cell. The new treatment has shown promising...

Read more

Biotech Industry Leader Andrew Young from Wellesley Launches New Personal Website

November 19, 2024 12:00 PM

Andrew Young, the esteemed CEO and Managing Partner of Conjugate Group, a renowned biotechnology staffing and business development firm, has officially launched his personal website. This new platform will serve as a hub for sharing his extensive professional experiences and offering valuable advice to the next generation of industry professionals. Andrew Young's career spans over two decades in the staffing industry, particularly in the biotech...

Read more

Alligator Announces Sale of Future Financial Commitments for Two Bispecific Antibodies to Orion Corporation

November 19, 2024 11:45 AM

Transaction valued at €3.5 million The partners have enjoyed a successful discovery collaboration since 2021 LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announced that the Company has entered into an agreement under which Orion Corporation has settled all future contractual milestones, royalty and any other commitments towards Alligator in relation to two preclinical bispecific antibodies resulting from...

Read more

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

November 19, 2024 8:15 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application have been submitted, reviewed and approved by the...

Read more

Next Gen Diagnostics Announces New York State Department of Health’s Wadsworth Center Has Joined the NGD Cefiderocol Data Consortium for the Sequencing-Based Determination of Cefiderocol Resistance

November 19, 2024 8:00 AM

CAMBRIDGE, MA AND ALBANY, NY / ACCESSWIRE / November 19, 2024 / Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence- (WGS-) based determination of bacterial susceptibility to antibiotics, and the Wadsworth Center, New York State Department of Health's public health laboratory, today announce an agreement providing for Wadsworth to join the NGD Cefiderocol Data Consortium,...

Read more

Bionoid Pharma, Inc. Launches Enhanced Supplements Ltd. to Drive Strategic E-Commerce Expansion

November 19, 2024 7:30 AM

TORONTO, ON / ACCESSWIRE / November 19, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is excited to announce the incorporation of its wholly owned subsidiary, Enhanced Supplements Ltd., a critical step in advancing the company's strategic transition to a robust e-commerce platform. This move is part of BINP's long-term growth plan to expand its market presence and diversify revenue streams. Enhanced Supplements Ltd. is specifically...

Read more

Adnexus Biotechnologies Inc. Appoints Dr. Hiroshi Ohrui to Scientific Advisory Board

November 19, 2024 7:00 AM

Adnexus Biotechnologies Inc. is pleased to announce the appointment of Dr. Hiroshi Ohrui to its Scientific Advisory Board. Dr. Ohrui is a distinguished expert in medicAinal chemistry and drug development, with a focus on antiviral therapies for HIV. Dr. Ohrui is best known for his pioneering work in the design and synthesis of Islatravir (formerly known as EFdA and MK-8591), an ultra-potent anti-HIV nucleoside drug in clinical development....

Read more

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

November 18, 2024 8:30 AM

Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q4 Investor Summit Presentation Time: 10:30am - 11:00am ET Location: https://www.webcaster4.com/Webcast/Page/3075/51674 The theme is 40 micro-cap companies with a catalyst and/or strong...

Read more

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

November 18, 2024 8:00 AM

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025 BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in...

Read more

CaaMTech's Psychedelic Functional Unblinding Strategy Gets Regulatory Blessing

November 14, 2024 5:05 PM

CaaMTech's New Clinical Trial Design Solves the Emergent Functional Unblinding Problems Plaguing Psychedelic Medicine Developers ISSAQUAH, WA / ACCESSWIRE / November 14, 2024 / CaaMTech, Inc. is pleased to announce positive feedback from United States federal government regulators for its CT-4201 psilocin prodrug program. Amongst other topics, the regulator's feedback validated CaaMTech's plan for functional unblinding of its CT-4201 drug...

Read more

Cloud Storage Security Launches Antimalware for Azure Blob

November 14, 2024 11:00 AM

Cloud Storage Security (CSS), a leader in advanced threat detection and data loss prevention for cloud-native applications, today announced availability of its multi-cloud antimalware solution supporting data stored on the Microsoft Azure and Amazon Web Services (AWS) platforms. CSS's multi-cloud solution provides a unified console to manage malware and virus scanning across both platforms in most regions, and is available for purchase through...

Read more